Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triazavirin for Mild-Moderate COVID-19
NCT04581915Phase 3Terminated
- Sponsor
- Wits Health Consortium
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Wits Health Consortium. Started Sep 2020; status: terminated.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04581915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581915.